Literature DB >> 26568302

EB-virus latent membrane protein 1 potentiates the stemness of nasopharyngeal carcinoma via preferential activation of PI3K/AKT pathway by a positive feedback loop.

C-F Yang1,2, G-D Yang3, T-J Huang4, R Li5, Q-Q Chu6, L Xu1, M-S Wang2, M-D Cai2, L Zhong2, H-J Wei2, H-B Huang7, J-L Huang8, C-N Qian1,9, B-J Huang1.   

Abstract

Our previous study reported that Epstein-Barr virus(EBV)-encoded latent membrane protein 1 (LMP1) could induce development of CD44(+/High) stem-like cells in nasopharyngeal carcinoma (NPC). However, the molecular mechanisms that underlie modulation of cancer stem cells (CSCs) in NPC remain unclear. Here, we show that LMP1 induced CSC-like properties through promotion of the expression of epithelial-mesenchymal transition-like cellular markers and through alterations in differentiation markers. Furthermore, LMP1 activated and triggered phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathway, which subsequently stimulated expression of CSC markers, development of side population and tumor sphere formation. This suggests that PI3K/AKT pathway has an important role in the induction and maintenance of CSC properties in NPC. Similarly, PI3K/AKT pathway was also activated by phosphorylase in LMP1-induced CD44(+/High) cells. In addition, LMP1 greatly increased expression of miR-21 and downregulated expression of the miR-21 target, PTEN. Overexpression of miR-21 by transfection of miR-21 mimics into LMP1-transformed cells led to phosphorylase-mediated activation of the PI3K/AKT pathway and induction of CSCs. On the contrary, phosphorylation of the PI3K/AKT pathway and the expression of CSC were reversed by an miR-21 inhibitor. The specific inhibitor (Ly294002) of PI3K/AKT pathway significantly decreased expression of miR-21 and CSC markers and upregulated the expression of PTEN, which indicates that miR-21 and PTEN are the downstream effectors of PI3K/AKT and that expression of these two effectors are related to the development of NPC CSCs. Taken together, our novel findings indicate that LMP1, PI3K/AKT, miR-21 and PTEN constitute a positive feedback loop and have a key role in LMP1-induced CSCs in NPC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26568302     DOI: 10.1038/onc.2015.402

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  51 in total

Review 1.  Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications.

Authors:  Jiezhong Chen
Journal:  World J Virol       Date:  2012-12-12

2.  Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo.

Authors:  M Groszer; R Erickson; D D Scripture-Adams; R Lesche; A Trumpp; J A Zack; H I Kornblum; X Liu; H Wu
Journal:  Science       Date:  2001-11-01       Impact factor: 47.728

3.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

4.  MicroRNA-21 targets tumor suppressor genes in invasion and metastasis.

Authors:  Shuomin Zhu; Hailong Wu; Fangting Wu; Daotai Nie; Shijie Sheng; Yin-Yuan Mo
Journal:  Cell Res       Date:  2008-03       Impact factor: 25.617

5.  MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways.

Authors:  Longlong Bao; Yan Yan; Can Xu; Weidan Ji; Shuwen Shen; Gaoya Xu; Yong Zeng; Bin Sun; Haihua Qian; Lei Chen; Mengchao Wu; Changqing Su; Jie Chen
Journal:  Cancer Lett       Date:  2013-05-14       Impact factor: 8.679

Review 6.  Cancer stem cells in head and neck squamous cell cancer.

Authors:  Mark E P Prince; Laurie E Ailles
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

7.  miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN.

Authors:  Shou-Mei Yang; Cheng Huang; Xiao-Feng Li; Ming-Zhe Yu; Yong He; Jun Li
Journal:  Toxicology       Date:  2013-03-04       Impact factor: 4.221

8.  Impaired immunomodulatory function of chronic myeloid leukemia cancer stem cells and the possible mechanism involved in it.

Authors:  Zhu Xishan; Zhou Xinna; He Baoxin; Ren Jun
Journal:  Cancer Immunol Immunother       Date:  2012-11-21       Impact factor: 6.968

9.  Phenotypic characterization of human colorectal cancer stem cells.

Authors:  Piero Dalerba; Scott J Dylla; In-Kyung Park; Rui Liu; Xinhao Wang; Robert W Cho; Timothy Hoey; Austin Gurney; Emina H Huang; Diane M Simeone; Andrew A Shelton; Giorgio Parmiani; Chiara Castelli; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-04       Impact factor: 11.205

10.  Evaluation of LMP1 of Epstein-Barr virus as a therapeutic target by its inhibition.

Authors:  Adele Hannigan; Joanna B Wilson
Journal:  Mol Cancer       Date:  2010-07-09       Impact factor: 27.401

View more
  24 in total

Review 1.  The molecular march of primary and recurrent nasopharyngeal carcinoma.

Authors:  Nicholas J Campion; Munira Ally; Bernhard J Jank; Jahangir Ahmed; Ghassan Alusi
Journal:  Oncogene       Date:  2021-01-21       Impact factor: 9.867

Review 2.  Epstein-Barr virus infection and nasopharyngeal carcinoma.

Authors:  Sai Wah Tsao; Chi Man Tsang; Kwok Wai Lo
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-10-19       Impact factor: 6.237

3.  Epstein-Barr virus microRNA BART10-3p promotes dedifferentiation and proliferation of nasopharyngeal carcinoma by targeting ALK7.

Authors:  Wei-Jie Luo; Shi-Wei He; Wen-Qing Zou; Yin Zhao; Qing-Mei He; Xiao-Jing Yang; Rui Guo; Yan-Ping Mao
Journal:  Exp Biol Med (Maywood)       Date:  2021-08-23

4.  miR-141 is involved in BRD7-mediated cell proliferation and tumor formation through suppression of the PTEN/AKT pathway in nasopharyngeal carcinoma.

Authors:  Y Liu; R Zhao; H Wang; Y Luo; X Wang; W Niu; Y Zhou; Q Wen; S Fan; X Li; W Xiong; J Ma; X Li; M Tan; G Li; M Zhou
Journal:  Cell Death Dis       Date:  2016-03-24       Impact factor: 8.469

5.  A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway.

Authors:  Jing Liu; Changqie Pan; Lihong Guo; Mengwan Wu; Jing Guo; Sheng Peng; Qianying Wu; Qiang Zuo
Journal:  J Hematol Oncol       Date:  2016-08-31       Impact factor: 17.388

6.  Extracellular serglycin upregulates the CD44 receptor in an autocrine manner to maintain self-renewal in nasopharyngeal carcinoma cells by reciprocally activating the MAPK/β-catenin axis.

Authors:  Qiaoqiao Chu; Hongbing Huang; Tiejun Huang; Li Cao; Lixia Peng; Simei Shi; Lisheng Zheng; Liang Xu; Shijun Zhang; Jialing Huang; Xinjian Li; Chaonan Qian; Bijun Huang
Journal:  Cell Death Dis       Date:  2016-11-03       Impact factor: 8.469

7.  Epstein-Barr virus-derived circular RNA LMP2A induces stemness in EBV-associated gastric cancer.

Authors:  Li-Ping Gong; Jian-Ning Chen; Min Dong; Zhen-Dong Xiao; Zhi-Ying Feng; Yu-Hang Pan; Yu Zhang; Yu Du; Jing-Yue Zhang; Yuan-Hua Bi; Jun-Ting Huang; Jing Liang; Chun-Kui Shao
Journal:  EMBO Rep       Date:  2020-08-12       Impact factor: 8.807

8.  Cetuximab and Cisplatin Show Different Combination Effect in Nasopharyngeal Carcinoma Cells Lines via Inactivation of EGFR/AKT Signaling Pathway.

Authors:  Jiajia Gu; Li Yin; Jing Wu; Nan Zhang; Teng Huang; Kai Ding; Haixia Cao; Lin Xu; Xia He
Journal:  Biochem Res Int       Date:  2016-05-24

9.  Glutaredoxin 3 promotes nasopharyngeal carcinoma growth and metastasis via EGFR/Akt pathway and independent of ROS.

Authors:  Feng He; Lili Wei; Wenqi Luo; Zhipeng Liao; Bo Li; Xiaoying Zhou; Xue Xiao; Jingping You; Yufeng Chen; Shixing Zheng; Ping Li; Mariko Murata; Guangwu Huang; Zhe Zhang
Journal:  Oncotarget       Date:  2016-06-14

10.  CD44 and CD24 coordinate the reprogramming of nasopharyngeal carcinoma cells towards a cancer stem cell phenotype through STAT3 activation.

Authors:  Yao-An Shen; Chia-Yu Wang; Hui-Yen Chuang; John Jeng-Jong Hwang; Wei-Hsin Chi; Chih-Hung Shu; Ching-Yin Ho; Wing-Yin Li; Yann-Jang Chen
Journal:  Oncotarget       Date:  2016-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.